


*In the Claims:*

Claims 1-14. **(canceled)**

15. **(currently amended)** A polypharmacophore represented by formula **(II)**:



wherein:

R<sub>1</sub> is -CO<sub>2</sub>R<sub>4</sub> or -CON(R<sub>4</sub>)<sub>2</sub>;

R<sub>2</sub> represents independently for each occurrence H, F, Cl, Br, or I;

R<sub>3</sub> represents independently for each occurrence H, F, Cl, Br, or I;

R<sub>4</sub> represents independently for each occurrence H or alkyl; and

the stereochemical configuration of the carbon-carbon double bond is *Z*, *E*, or a mixture of *Z* and *E*.

Claims 16-54. **(canceled)**


55. **(previously presented)** The polypharmacophore of claim 15, wherein R<sub>2</sub> is F.

56. **(previously presented)** The polypharmacophore of claim 15, wherein R<sub>2</sub> is F and R<sub>3</sub> is H.

57. (canceled)

58. (currently amended) The polypharmacophore of claim 15, wherein ~~R<sub>1</sub> is CO<sub>2</sub>R<sub>4</sub>~~ and R<sub>4</sub> is H.

59. (currently amended) The polypharmacophore of claim 15, wherein said compound is selected from the group consisting of:




60. (currently amended) A pharmaceutical composition, comprising:

a polypharmacophore of claim 15, 55, 56, [[57,]] 58 or 59, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier.

61. (currently amended) A polypharmacophore selected from the group consisting of:





62. **(previously presented)** A pharmaceutical composition, comprising: a polypharmacophore of claim 61, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier.